PERANAN PROKALSITONIN PADA PNEUMONIA KOMUNITAS
Downloads
Abstrak : Keterbatasan dalam mendiagnosis infeksi respirasi dari klinis, gejala penyakit dan pemeriksaan mikrobiologis, keberadaan biomarker dapat dijadikan informasi tambahan dalam meningkatkan diagnosis dan prognosis yang membantu dalam keputusan pemberian terapi. Penggunaan prokalsitonin dapat membantu diagnosis membedakan dari infeksi yang disebabkan oleh virus, menilai derajat risiko pasien dan keputusan pemberian, penghentian dan durasi antibiotik yang optimal. Pneumonia komunitas masih menjadi masalah kesehatan. Prokalsitonin pada akhir-akhir ini menjadi perhatian prognosis pada pneumonia komunitas. , baik yang diakibatkan oleh bakter iatau pun bukan. Prokalsitonin juga mempunyai kemampuan yang lebih baik dari pada C-reaktif protein sebagai biomarker petanda inflamasi dan mempunyai hubungan yang signifikan dengan skor sistem yang menilai klinis dan angka kematian. Kata kunci: Pneumonia komunitas, prokalsitonin
Abstract : In light of the limitations of clinical signs and symptoms and traditional microbiologic diagnostic for respiratory infections, blood biomarkers that correlate with the presence and extent of bacterial infections may provide additional useful information to improve diagnostic and prognostic efforts and help with therapeutic decisions in individual patients. A growing body of evidence support the use of procalcitonin (PCT) to differentiate bacterial from viral respiratory diagnoses, to help risk stratify patients, and to guide antibiotic therapy decisions about initial need for, and optimal duration of, therapy.Communityacquired peneumonia (CAP) is a significant clinical and public health problem. Recently, attention has been paid to the potential for procalcitonin (PCT) both to differentiate the diagnosis and to indicate the prognosis of pneumonia. Procalsitonin has the ability to supplement clinical information to determine whether or not the cause of the inection is likely to be bacterial. In addition, PCT seems to be superior to the most prevalent inflammatory biomarker C-reactive protein a
Downloads
Soepandi PZ, Burhan E, Nawas A, Giriputro S, Isbaniah F, Agustin H, et al. Pneumonia komunitas. Jakarta : PDPI;2014:1-19.
Schuetz P, Amin DN, Greenwald JL, Role of procalcitonin in managing adult patient with respiratory tract infection. Chest. 2012;141(4):1063-73.
Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarker for personalized management decisionsb
in community acquired pneumonia. Curr Opin Infect Dis. 2013;26:159-67.
Sudoyo AW, Setiyohadi B, Alwi I. Pneumonia. Ilmu Penyakit Dalam. Jakarta : Penerbit; IPD FKUI;2006:965-71.
Buchori, Prihartini. Diagnosis sepsis menggunakan prokalsitonin. Indonesian Journal of linical Pathology and Medical Laboratory. 2006;12(3):131-7.
Masia M, Gutiérrez F, Shum C, Padilla S, Navarro JC, Flores E, et al. Usefulness of procalcitonin levels in community acquired pneumonia according to the patients outcomes research team pneumonia severity index. Chest. 2005;128:2223-9.
Mandell LA, Wunderink RG, Azueto A. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults: Clin Infect Dis. 2007;44:s27-72.
Agarwal S, Meena M, Misra A, Meena L, Singh M. A study to compare prognostic utility of procalcitonin with existing biomarkers (CRP and TLC) and clinical risk score (PSI and CURB65) in community acquired pneumonia. National Journal of Physiology, Pharmacy & Pharmacology. 2015;5:28-32.
Mandell L, Marrie T, Grossman R. Canadian guidelines for the initial management of community acquired pneumonia: an evidence based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31:383-421.
Dasaraju PV, Liu C. Infections in respiratory system. [cited on January, 1st 2009]. Available from :.
Wunderink http://gsbs.utmb.edu/ microbook/ch093.htm RG. A CAP on antibiotic duration. Am J Respir Crit Care Med. 2006;174:3-5.
Becker KL, Nyle’n ES, White JC, Muller B, Snider RH. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection and sepsis : a journey from calcitoninback to its precursors. J Clin Endocrinol Metab. 2004;89:1512-25.
Kristopher AM, Baumann NA. Clinical laboratory news: procalcitonin. AACC. 2009; 35(7).
Kibe S, Adams K, Barlow G, Diagnostic and prognostic biomarkers of sepsis in clinical care. J.Antimicrob Chemoter. 2011;66(suppl 2):i33-40.
Vienna. Procalcitonin: a new marker of the systemic inflammatory response to infections. Clinic Anesthestiology and Intensive Care. Germany. April. 2000.
Korppi M, Remes S. Serum prokalsitonin in pneumococcal pneumonia in children. Eur Respir J.2001;17:623-7.
Kiriyama Y, Nomura Y, Tokumitsu Y. Calcitonin gene expression induced by lipopolysaccharide in the rat pituitary. Am J Physiology Endocrinol Metab. 2002;282:1380-4.
Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and,tuberculosis. Eur Respir J. 2003;939-4.
Schleicher GK. Procalcitonin and c-reactive protein levels in HIVpositive subject with tuberculosis and pneumonia. Eur Respir J.2005;25:688-92.
Crain C, Stolz DJ, Bingisser R, Gencay MM, Huber PR, Tamm M et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections:cluster-randomised,singleblinded interventional trial. Lancet. 2004; 363:600-7.
Crain MC. Procalcitonin guidance of antibiotic therapy in community acquired pneumonia. Am J Respir Crit Care Med. 2006;174:84-93
